NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 12/02/2022 06:00
Last Report Issued 07/19/2022 13:29

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name NA
Patient ID 2531SP
Chain 22001870
DOB Not Given
Sex Not Given
Workorder 22001870

Received 07/19/2022

Lab ID 22001870-001
Matrix Serum or Plasma
Patient Name NA
Patient ID 2531SP
Container Type Black Cap Glass Container

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
2531SP Leflunomide as Metabolite (Therapeutic Drug Monitoring), Serum/Plasma				
Analysis by High Performance Liquid Chromatography/ Tandem Mass Spectrometry (LC-MS/MS)				
Teriflunomide	None Detected	ng/mL	500	

Synonym(s): Leflunomide Metabolite

Leflunomide is used for the management of the signs and symptoms of rheumatoid arthritis. Teriflunomide is an active metabolite of Leflunomide and is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Mean steady-state trough plasma concentrations of teriflunomide from patients on daily regimens of 10 or 25 mg of leflunomide were 18000 and 63000 ng/mL, respectively, after 24 days. Recommended doses of teriflunomide and leflunomide result in a similar range of teriflunomide plasma concentrations. Based on this, the expected therapeutic range is between 18000 ng/mL and 63000 ng/mL.

Results for sample 22001870-001 are continued on next page

NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Lab ID 22001870-001
Matrix Serum or Plasma
Patient Name NA
Patient ID 2531SP

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
Following completion of an elimination regimen, plasma concentrations should be determined twice at least 14 days apart to verify that concentrations are less than 20 ng/mL. THIS TEST IS NOT MEANT TO MONITOR THE ELIMINATION OF TERIFLUNOMIDE IN WOMEN OF CHILDBEARING POTENTIAL WHO DISCONTINUE LEFLUNOMIDE. The drug carries a black box warning for hepatotoxicity and pregnancy.				

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.